Zydus Lifesciences, based in Ahmedabad, India, has announced its acquisition of Assertio Holdings Inc., a Nasdaq-listed pharmaceutical company, for $166.4 million in an all-cash deal. Assertio specializes in oncology supportive-care therapies, and this acquisition will provide Zydus with an established commercial platform in the US oncology market. The agreement includes a purchase price of $23.50 per share, marking a 30.6% premium over Assertio's prior agreement with Garda Therapeutics. Zydus's managing director, Sharvil Patel, emphasized that this acquisition aligns with their long-term strategy to enhance their specialty and oncology presence globally. The deal is structured as a tender offer, expected to commence within five business days, and is anticipated to close within the current financial year, contingent on meeting all closing conditions. This acquisition is part of Zydus's broader strategy to diversify its portfolio, following previous acquisitions in biologics and medtech sectors.